A high-throughput drug screening system for HIV-1 transcription inhibitors

被引:4
作者
Kempf, Mirjam-Colette
Jones, Jennifer
Heil, Marintha L.
Kutsch, Olaf
机构
[1] Univ Alabama, Div Hematol Oncol, BBRB, Dept Epidemiol, Birmingham, AL 35294 USA
[2] Univ Alabama, Dept Med, Birmingham, AL 35294 USA
关键词
HIV-1; infection; Tat; high-throughput drug screening; fluorescent proteins;
D O I
10.1177/1087057106290292
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Identification of HIV-1 transcription inhibitors was previously performed using infectivity assays. As de novo HIV-1 infection is highly sensitive to even minor compound toxicities, these assays are plagued by extremely high levels of false-positive hits. Hit identification is further complicated because infectivity assays lack target specificity. The authors demonstrate that it is possible to overcome these limitations by establishing a stable, chronically actively HIV-1-infected reporter cell line that exclusively identifies HIV-1 transcription inhibitors. In the reporter cell line, 2 spectrally separated fluorescence proteins serve as simultaneously accessible quantitative markers of HIV-1 expression and drug toxicity. The combined analysis of these markers drastically reduces the level of false-positive hits. As determination of fluorescence intensity in a plate-based format can be performed in a noninvasive manner, repeated measurements of fluorescence levels over several days after compound addition can be used to define the kinetic and dynamic characteristics of inhibitory drug effects. In addition, because of the stable nature of the reporter cell line, the assay requires no cell manipulation during assay preparation or assay analysis, rendering the system extremely cost-effective and reliable.
引用
收藏
页码:807 / 815
页数:9
相关论文
共 31 条
[1]   THE STRUCTURE OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TAR RNA REVEALS PRINCIPLES OF RNA RECOGNITION BY TAT PROTEIN [J].
ABOULELA, F ;
KARN, J ;
VARANI, G .
JOURNAL OF MOLECULAR BIOLOGY, 1995, 253 (02) :313-332
[2]  
Baba M, 1998, MOL PHARMACOL, V53, P1097
[3]   Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives [J].
Baba, M ;
Okamoto, M ;
Makino, M ;
Kimura, Y ;
Ikeuchi, T ;
Sakaguchi, T ;
Okamoto, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1250-1255
[4]   The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism [J].
Bailly, C ;
Colson, P ;
Houssier, C ;
Hamy, F .
NUCLEIC ACIDS RESEARCH, 1996, 24 (08) :1460-1464
[5]   Solution structure of the HIV-2 TAR-argininamide complex [J].
Brodsky, AS ;
Williamson, JR .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 267 (03) :624-639
[6]   NMR evidence for a base triple in the HIV-2 TAR C-G•C+ mutant argininamide complex [J].
Brodsky, AS ;
Erlacher, HA ;
Williamson, JR .
NUCLEIC ACIDS RESEARCH, 1998, 26 (08) :1991-1995
[7]   Binding of Hoechst 33258 to the TAR RNA of HIV-1. Recognition of a pyrimidine bulge-dependent structure [J].
Dassonneville, L ;
Hamy, F ;
Colson, P ;
Houssier, C ;
Bailly, C .
NUCLEIC ACIDS RESEARCH, 1997, 25 (22) :4487-4492
[8]   Electron paramagnetic resonance dynamic signatures of TAR RNA - Small molecule complexes provide insight into RNA structure and recognition [J].
Edwards, TE ;
Sigurdsson, ST .
BIOCHEMISTRY, 2002, 41 (50) :14843-14847
[9]   Structural rearrangements of HIV-1 Tat-responsive RNA upon binding of neomycin B [J].
Faber, C ;
Sticht, H ;
Schweimer, K ;
Rösch, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (27) :20660-20666
[10]   Viral dynamics and anti-viral pharmacodynamics:: rethinking in vitro measures of drug potency [J].
Ferguson, NM ;
Fraser, C ;
Anderson, RM .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (02) :97-100